A phase II trial of chemotherapy-free neoadjuvant camrelizumab plus apatinib for resectable HNSCC: pathological response and vascular-immune crosstalk.

AiTan (rivoceranib) - Elevar Therapeutics

AiRuiKa (camrelizumab) - Elevar Therapeutics

http://www.ncbi.nlm.nih.gov/pubmed/42714868

Alfred King-Yin Lam; Bin Qiao; Jie Qiao; Li Zhang; Lihuang Chen; Min Li; Xin'guang Han; Yaqiong Jie; Yi Liu; Yushuo Zhang; Zhuo Chen

Sep 10, 2026